1. At a Glance
Bharat Rasayan Ltd is that low-profile nerd in class who secretly topped the board exams but refused to attend the party. A stock that trades above ₹11,000, with a market cap close to ₹4,800 Cr, yet offers a dividend yield of 0.01% — so low, it could be mistaken for a decimal error. Still, Q1FY26 net profit has more than doubled, and OPM has bounced back to 19%. Something’s brewing in this agrochemical cauldron.
2. Introduction: The Silent Assassin of Agrochemicals
No ads. No flashy investor calls. Just quiet execution. Bharat Rasayan doesn’t sell pesticides to consumers — it sells power to giants. A hardcore B2B manufacturer of technical-grade pesticides and chemical intermediates, the company is the supplier behind your favourite crop-protecting brands.
But don’t be fooled by its silence. In the last 10 years, the stock has given a 27% CAGR return — quietly compounding like a chemist in a locked lab. Now, as the chemical cycle shows signs of revival, Bharat Rasayan is crawling back into the spotlight… with ₹377 Cr in quarterly sales and a respectable ₹44 Cr PAT.
3. Business Model (WTF Do They Even Do?)
Bharat Rasayan is the chemical factory behind your favourite agrochem brand’s success. It doesn’t market fancy sachets — it sells molecules. The company produces:
- Insecticides: Lambda Cyhalothrin, Fipronil, Thiamethoxam
- Intermediates: Metaphenoxy Benzaldehyde, Metribuzine
- New launches: Fluxametamide, Diuron, Tolfenpyrad
It specializes in backward-integrated manufacturing, with tight control over its supply chain. 66% of sales come from just 10 products. That’s either highly focused execution — or a concentration risk that could turn into a margin slasher overnight.
4. Financials Overview
Q1 FY26 (Standalone):
- Revenue: ₹377 Cr (+33.7% YoY)
- EBITDA: ₹73 Cr
- PAT:
- ₹44 Cr (+103% YoY)
- EPS (Qtr): ₹105.07 → Annualized EPS ~₹420
- Recalculated P/E: ₹11,499 / ₹420 ≈27.4x
- ROCE: 15.4% |ROE: 12.0%
TTM Sales: ₹1,268 CrTTM PAT: ₹142 Cr
💡After two years of margin stress, FY25 and Q1FY26 show operating recovery and normalization.
5. Valuation (Fair Value RANGE only)
Method | Calculation | Fair Value (₹) |
---|---|---|
P/E Method | EPS ₹420 × 25–30 | ₹10,500–₹12,600 |
EV/EBITDA | EBITDA ₹210 Cr × 10–12 | ₹10,000–₹12,000 |
DCF (Assume 10% CAGR, 11% WACC) | Equity value est. ~₹4,800–5,500 Cr | ₹11,000–₹12,500 |
Fair Value Range: ₹10,000 – ₹12,600
“This FV range is for educational purposes only and is not investment advice.”
6. What’s Cooking – News, Triggers, Drama
- Q1FY26 PAT doubledYoY — clear margin recovery
- OPM improved to 19%from 13% in Q4FY25
- Dividend declaredat 15% (₹1.5/share) after years of ignoring shareholders
- Volume clarification notice from BSEin June = spike watchers beware
- No promoter churn, no FII exits = stable ownership
- China+1 advantageand global de-risking of chemical supply chains could help exports
7. Balance Sheet – Old School Solid
Metric | FY25 (₹ Cr) |
---|---|
Equity Capital | ₹4 Cr |
Reserves | ₹1,102 Cr |
Borrowings | ₹85 Cr |
Net Worth | ₹1,106 Cr |
Total Assets | ₹1,385 Cr |